27.10
-0.35 (-1.26%)
AIStockmoo Score
| Value 30% | -0.8 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Timing 30% | -2.0 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 3.5 |
| Insider Activity info | NA |
| Institutions net +16.17% of shares in their latest 13F filings: 199 holders increased, 147 decreased (quarter to 30 Sep 2026). info | |
| Short interest -7.1% from 31 Aug to 30 Oct 2026, 8.7 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| No clear signal from support and resistance. info | |
| Final Score | -0.13 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cogent Biosciences, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| COGT | - | - | - | 11.00 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| ACAD | - | - | - | 2.34 |
| CYTK | - | - | - | - |
Select this tab to load the latest available analysis.
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 103.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,503,418 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 125.70%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 199 | 35,045,215 |
| Decreased | 147 | 17,227,854 |
| New | 57 | 13,674,570 |
| Sold out | 58 | 3,356,114 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 17,416,118 | 8.7 |
| 15 Oct 2026 | 19,661,566 | 8.9 |
| 30 Sep 2026 | 19,462,718 | 8.1 |
| 15 Sep 2026 | 18,126,492 | 11.8 |
| 31 Aug 2026 | 18,747,531 | 12.1 |
| 14 Aug 2026 | 18,411,111 | 8.9 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
Cogent Biosciences (COGT) reported widening third quarter losses and a busy regulatory calendar, posting a net loss of US$111.43 million as it approaches several FDA decisions on bezuclastinib. Cogent Biosciences’ share price has come under pressure in recent months, with the stock down about 30%… |
| 05 Nov 2026 | Yahoo Finance |
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.… |
| 27 Oct 2026 | Yahoo Finance |
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual… |
| 20 Oct 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November… |
| 25 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s… |
| 24 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased… |
| 24 Sep 2026 | Yahoo Finance |
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal… |
| 15 Sep 2026 | Yahoo Finance |
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent… |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |